Clinical and Molecular Landscape of Amyotrophic Lateral Sclerosis Patients with OPTN Variants from Turkey and Possible Therapeutic Response to Inhibation of RIPK1
Hacer Durmus1, Ebru Erzurumluoğlu2, Duygu Gezen-ak3, Erdinç Dursun3, Merve Alaylioglu3, Arman Cakar4, Oya Uyguner5, Esen Kiyan6, Fatma Yesim Parman7
1Department of Neurology, Istanbul Faculty of Medicine, 2Genetics, Eskişehir Osmangazi Univeristy, 3Brain and Neurodegenerative Disorders Research Laboratories, Department of Neuroscience, Institute of Neurological Sciences, Istanbul University-Cerrahpasa, Istanbul Turkey, 4Istanbul Üni. Çapa, 5Istanbul Faculty of Medicine, 6Istanbul University, Istanbul Faculty of Medicine, Department of Pulmonary Medicine, Istanbul, Turkey, 7Istanbul Üniversitesi Tip Fakültesi
Objective:

In this study, we aim to define detailed clinical and genetic characteristics of patients with variants in OPTN from Turkey. Here we also describe the baseline characteristics, treatment and safety outcomes of three patients with OPTN-ALS treated with primidone, a RIPK1 inhibitor drug.

Background:

Previously linked to primary open-angle glaucoma, OPTN is now also identified as a rare cause of familial and sporadic ALS. Optineurin inhibits RIPK1-dependent inflammatory and cell death mechanism. Loss of optineurin function may sensitize motor neurons to RIPK1 kinase activation and RIPK1-dependent programmed cell death leading to ALS.

Design/Methods:

Ten patients diagnosed with definite or probable ALS according to El-Escorial criteria, who carried genetically confirmed pathogenic variants in OPTN. Primidone, FDA-approved drug for seizures has not been approved for ALS. We obtained signed informed consent from all patients, who then underwent 6-minute walk test (6MWT), ALSFRS-R and forced vital capacity. Serum NFL, RIPK and GFAP levels were also recorded.

Results:

Three patients were female and two were sporadic. The mean age of onset was 40 years. Upper motor neuron signs were prominent in all patients. Three homozygous pathogenic/likely pathogenic variant in the OPTN gene (NM_001008212.2) were identified (c.872del/p.(Gly291AlafsTer12), c.1078_1079delAA/(Lys360Valfs*18)  and (c.1400A>C/p.(Gln467Pro)). Three patient received primidone 250mg per day for three months. No changes in ALSFRS-R and FVC were observed at 3th month but the distance walked improved in two patients, mean baseline 6MWT distances was 87.5 m, mean 6MWT distance was 146.5 m after 3 months of treatment. Mean sNFL of these two was 38.1 pg/ml at baseline, 42.75 pg/ml at the first month and decreased to 35 pg/ml at 3th month. Mean sGFAP was also decreased from 128.5 pg/ml at baseline to 113.6 pg/ml at 3th month.

 

Conclusions:

The clinical association of OPTN exhibits allelic heterogeneity. Repurposing primidone, an FDA approved RIPK inhibitor may have beneficial effects in OPTN-ALS.

10.1212/WNL.0000000000211223
Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff.